Stay updated on Surufatinib, Toripalimab & Chemo in 2nd-line CRC Clinical Trial
Sign up to get notified when there's something new on the Surufatinib, Toripalimab & Chemo in 2nd-line CRC Clinical Trial page.

Latest updates to the Surufatinib, Toripalimab & Chemo in 2nd-line CRC Clinical Trial page
- Check4 days agoNo Change Detected
- Check11 days agoChange DetectedThe clinical trial record for surufatinib, toripalimab, and chemotherapy in second-line colorectal cancer is displayed instead of an error page. It provides study design, eligibility requirements, contacts and location, and measured outcomes.SummaryDifference46%

- Check18 days agoChange DetectedThe ClinicalTrials.gov footer revision changes from v3.7.2 to v3.8.0, while the page continues to show a 403 Forbidden error.SummaryDifference0.2%

- Check25 days agoChange DetectedA site-wide notice announces NIH website updates and says that “Super Intelligence” (SI) is being used in place of “Artificial Intelligence” (AI) during the transition.SummaryDifference1%

- Check32 days agoChange DetectedThe site's displayed revision identifier changed from v3.7.1 to v3.7.2.SummaryDifference0.2%

- Check39 days agoChange DetectedThe site footer now displays revision v3.7.1 instead of v3.7.0.SummaryDifference0.2%

- Check60 days agoChange DetectedThe page now displays a 403 Forbidden error instead of the study record, indicating restricted access to the study details.SummaryDifference18%

Stay in the know with updates to Surufatinib, Toripalimab & Chemo in 2nd-line CRC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Surufatinib, Toripalimab & Chemo in 2nd-line CRC Clinical Trial page.